eik1005
eik1005: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Eikon Therapeutics Inc. (EIKN) | Phase 2/Phase 3 |
Clinical Trials (1)
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naïve Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors
Frequently asked questions
Who is developing eik1005?
eik1005 is being developed by Eikon Therapeutics Inc..
How many clinical trials involve eik1005?
BioSniper tracks 1 clinical trial involving eik1005.
Get deeper analysis on eik1005
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis